A Closer Look at Linde (LIN) Shares: Pipelines and Cylinders

Industrial gases are one of the few businesses where the product is almost invisible and the contract is the real asset. Oxygen, nitrogen, argon, hydrogen and helium are commodities, yet the companies that supply them earn margins closer to software than to chemicals. Any Linde stock analysis has to start there, because Linde plc (LIN) is the largest of the three global majors and the structure of how it sells gas explains most of what shows up in its income statement. This article walks through how the company earns its money, what its most recent reported figures show, how its project backlog works, and which numbers would most change the picture from here.

How Linde Makes Its Money

Linde reports revenue by how the gas reaches the customer, and the split is instructive. For the full year 2025, on total sales of roughly $34.0 billion, packaged gas was the largest slice at about $11.85 billion, or 35% of sales. Merchant supply came next at roughly $10.16 billion, or 30%. On-site supply was about $8.08 billion, or 24%. The remaining 11%, roughly $3.89 billion, sits in other businesses, of which Linde Engineering was about $2.25 billion.

Those three channels behave very differently. On-site supply is for customers with large, steady volumes: a steel mill, a refinery, a chemical complex or a semiconductor fab. Linde builds an air separation unit or hydrogen plant on or next to the customer's site and pipes the product straight over the fence. The company's own filings describe these as total requirement contracts with terms typically running 10 to 20 years, containing minimum purchase requirements and price escalation provisions. In plain terms, the customer is committed to buy, there is a floor under the volume, and inflation can be passed through contractually. Linde disclosed future minimum purchase commitments on its on-site and engineering contracts of roughly $62 billion as of the end of 2025, and that figure excludes any sales above the contracted minimums.

Merchant supply, the middle tier, delivers liquefied gas by tanker truck to customers too small for a dedicated plant, on contracts that typically run about three to seven years. Packaged gas is the cylinder business: welding gases, medical oxygen, specialty mixtures, sold to small customers through a distribution network. Packaged gas carries the shortest contracts and the most exposure to industrial activity, but it also carries high density and local pricing power, and in the Americas alone it generated about $6.46 billion of 2025 sales.

The practical consequence is that a large part of Linde's revenue base is contracted years ahead with pass-through mechanisms attached, while the shorter-cycle packaged and merchant business flexes with manufacturing demand. That mix is why the company's sales line moves less violently than the industrial cycle it serves.

Where a Linde Stock Analysis Starts: The Latest Reported Numbers

The most recent period Linde has reported is the second quarter of 2026, published on 31 July 2026. Sales were $9,289 million, up 9% year over year, with underlying sales up 4%. Reported diluted earnings per share were $4.15, up 11% from $3.73 in the second quarter of 2025. On the company's adjusted basis, diluted EPS was $4.50, up 10% from $4.09. The reported operating margin was 27.5% and the adjusted operating margin 29.5%.

The quarter before, the first quarter of 2026, showed a similar shape: sales of $8,781 million, up 8% with underlying sales up 3%; reported EPS of $3.98, up 13%; adjusted EPS of $4.33, up 10%; an adjusted operating margin of 30.0% and a reported margin of 27.8%.

For context, full-year 2025 sales were about $34.0 billion, up 3% with underlying sales up 2%, and adjusted EPS was $16.46, up 6%. Management reiterated full-year 2026 adjusted EPS guidance of $17.70 to $17.90 alongside the second-quarter release, implying 8% to 9% growth, having narrowed upward from an original February range of $17.40 to $17.90. Third-quarter adjusted EPS guidance was set at $4.45 to $4.55.

The pattern across those periods is worth naming precisely: reported sales growth has been running ahead of underlying growth, meaning acquisitions, cost pass-through and currency are contributing, while earnings per share growth has been running ahead of sales growth, which points to pricing, productivity and a shrinking share count rather than volume as the main engine.

Margins, Return on Capital and the Home Care Drag

Margins were the sore point in the second quarter. The adjusted operating margin of 29.5% was 60 basis points below the prior year, or 30 basis points lower excluding the effect of cost pass-through, which mechanically inflates both sales and costs without adding profit. Management said on the earnings call that it was not satisfied with the quarter's margin performance.

The segment detail shows where the pressure sat. In the Americas, sales were $4,083 million, up 7%, with an operating margin of 31.2%, down 50 basis points. Management attributed the drag to the U.S. home care business, Lincare, citing labor cost inflation and changes in the reimbursement environment, and said the Americas margin would have been up about 20 basis points excluding that business. EMEA delivered sales of $2,303 million, up 7% as reported but only 1% underlying, with operating profit of $823 million for a 35.7% margin, down 40 basis points but up 10 basis points excluding cost pass-through. Asia Pacific grew fastest, with sales of $1,870 million, up 13% as reported and 8% underlying on 6% volume growth, though its operating margin of 28.4% fell 120 basis points, or 70 basis points excluding pass-through. Linde Engineering, the project arm, posted sales of $625 million, up 13%, operating profit of $100 million for a 16.0% margin, and order intake of $871 million.

Return on capital, which measures how much operating profit the business generates per dollar of capital employed, was 23.5% in the second quarter. For a capital-intensive business that spends billions a year on plants, that figure is the single most informative number in the release, because it shows whether new capacity is being added at returns above the cost of funding it. Management has said it expects sequential margin improvement into the third quarter and is evaluating strategic options for the home care business.

The Project Backlog and the Growth Pipeline

Because on-site plants take years to build, Linde discloses a project backlog that functions as a forward order book. At the end of the second quarter of 2026 the total backlog stood at a record of roughly $11.1 billion. The sale-of-gas portion, which becomes Linde's own long-term contracted revenue once the plant starts up, reached a record $8.1 billion after around $1 billion of new U.S. electronics wins tied to advanced-node semiconductor fabs. The remaining roughly $3.0 billion is sale-of-plant work, where Linde Engineering designs and builds for third parties under signed agreements.

The composition matters as much as the total. Chemicals accounted for about 56% of the backlog and electronics about 22%, and management expects electronics to remain the largest single contributor for the foreseeable future. Separately, a Taiwan joint venture's electronics wins, representing roughly $800 million of investment, sit outside the reported backlog. Management guided to starting more than 20 projects, about $1.3 billion of investment, across the rest of 2026, and expects the sale-of-gas backlog to finish the year around the $8 billion mark.

For readers tracking the growth path, the backlog is the mechanism that converts today's capital spending into tomorrow's contracted revenue. The questions it raises are about conversion: whether projects start on schedule, whether returns hold at the level the company targets, and whether the electronics concentration becomes a dependence on one capital cycle.

Cash Flow, the Balance Sheet and the Dividend

Cash generation has been steady. Operating cash flow was $2,240 million in the first quarter of 2026, up 4%, and $2,271 million in the second, up 3%. Capital expenditure was $1,342 million and $1,438 million in those quarters respectively, leaving free cash flow of $898 million and $833 million. Across the first half, that is roughly $4.5 billion of operating cash flow against $2.8 billion of capex. The comparison with 2025 is useful: for that full year Linde generated $10.4 billion of operating cash flow, invested $5.3 billion in capital expenditure and returned $7.4 billion to shareholders.

Shareholder returns in 2026 have continued at a similar clip, at $1,545 million in the first quarter and $1,590 million in the second, though net share purchases of $1,656 million across the first half were below the $2,207 million bought in the first half of 2025. On the balance sheet, the second-quarter filing showed total debt of roughly $28.0 billion against shareholders' equity of about $39.1 billion, with a $5.0 billion and a $1.5 billion unsecured revolving credit agreement both undrawn and no borrowings outstanding under them.

The dividend has one of the longer unbroken records in the market. In February 2026 the board raised the quarterly rate 7% to $1.60 per share, the 33rd consecutive annual increase, first paid on 26 March 2026, and the rate has been held at that level in subsequent 2026 declarations. The 2025 increase was 8%, the 32nd consecutive year.

Valuation Metrics and the Main Risks

Around mid-October 2026 the shares traded in the mid-$480s, with market data providers putting the market capitalization at roughly $223 billion to $226 billion and the 52-week range at approximately $388 to $548. On those quotes the forward price-to-earnings multiple was around 25.9 times, against a trailing multiple in the region of 28 to 31 times. The forward multiple simply divides the share price by expected earnings per share for the year ahead, so it compresses when guidance rises and expands when the price rises faster than estimates; the gap between the trailing and forward figures here reflects the 8% to 9% EPS growth management has guided to. Market prices move daily, and these figures are a snapshot rather than a fixed input.

The risks sit in identifiable places. Packaged and merchant volumes track industrial production, so a manufacturing slowdown in Europe or North America feeds through quickly. Cost pass-through smooths energy inflation but distorts reported margins in both directions. The home care business has been a persistent margin headwind driven by labor costs and reimbursement, and the outcome of the strategic review is unresolved. The electronics-weighted backlog links a growing share of future contracted revenue to semiconductor capital spending, which is cyclical. And with total debt near $28 billion, the cost of refinancing matters to a company that funds long-lived assets.

What to Watch From Here

Linde's third-quarter 2026 results are scheduled for 29 October 2026, and three lines in that release carry most of the information. The first is the adjusted operating margin: management has guided to sequential improvement from 29.5%, and whether the Americas segment turns without excluding the home care business is the test. The second is the sale-of-gas backlog, which the company expects to end the year near $8 billion, and the pace at which projects move from backlog into operating plants. The third is return on capital, running at 23.5% in the second quarter, which shows whether the heavy capital spending behind that backlog is being deployed at returns consistent with past performance.

Alongside those, the strategic review of the U.S. home care business and the full-year adjusted EPS outturn against the $17.70 to $17.90 guidance range are the items most likely to move the picture. Compared with its peers, Air Products (APD) and the Paris-listed Air Liquide, Linde operates the same contract-led model, and investors looking at any one of them are really comparing margin trajectory, backlog quality and capital discipline. For Linde specifically, the figures above are the scaffolding; the next reporting period will show which way they are bending.